You can detect circulating epithelial tumor cells (CETC) in blood samples of cancer patients (also breast cancer patients) by fluorescent anti-EpCAM antibodies and fluorescence microscopy. The number of CETCs in blood or lymph fluid is correlated with the risk of relapse and metastasis formation.
As Dr Bernhard Biersack mentioned, circulating tumor cells (CTC) with EpCAM expression is widely recognized in the clinical settings. However, given that EpCAM tends to be expressed in epithelial tissue-origin tumors, the detection derived from sarcomas seems to be challenging.
Furthermore, the cell-lineage tracing from primary site is much more difficult in the human body, I think. Once pre-metastatic niche or distant metastatic tissue forms, the origin of the tumor cells in the bloodstream is no longer identified.